Molecular imaging study using 18F-fluoromisonidazole PET/CT for Stage I Non-Small Cell Lung Cancer Treated by Stereotactic Body Radiotherapy
Project/Area Number |
25461897
|
Research Category |
Grant-in-Aid for Scientific Research (C)
|
Allocation Type | Multi-year Fund |
Section | 一般 |
Research Field |
Radiation science
|
Research Institution | Hokkaido University |
Principal Investigator |
INOUE TETSUYA 北海道大学, 大学病院, 助教 (10431363)
|
Co-Investigator(Kenkyū-buntansha) |
OIZUMI SATOSHI 北海道大学, 大学院医学研究科, 准教授 (10421968)
SHIGA TORU 北海道大学, 大学院医学研究科, 准教授 (80374495)
|
Project Period (FY) |
2013-04-01 – 2016-03-31
|
Project Status |
Completed (Fiscal Year 2015)
|
Budget Amount *help |
¥4,810,000 (Direct Cost: ¥3,700,000、Indirect Cost: ¥1,110,000)
Fiscal Year 2015: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2014: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2013: ¥2,210,000 (Direct Cost: ¥1,700,000、Indirect Cost: ¥510,000)
|
Keywords | 低酸素イメージング / 定位放射線治療 / FMISO / 体幹部定位放射線治療 |
Outline of Final Research Achievements |
The purpose of this study is to clarify the existence of hypoxic regions and changes after stereotactic body radiotherapy (SBRT) in stage I non-small cell lung cancer (NSCLC). From September 2013 to December 2014, 12 patients with histopathologically confirmed stage I NSCLC were enrolled. 18F-fluoromisonidazole (FMISO)-PET/CT was performed before SBRT for all patients, and FMISO-PET/CT was performed again within 1 month after SBRT in principle. We calculated that the upper threshold of the SUVmax of normal muscle was calculated to be 1.60, so we regarded the accumulation of FMISO > 1.60 as indicating hypoxic region. A hypoxic region was observed in 7 patients (7/12, 58%). FMISO-PET/CT was performed after SBRT in five of the patients with a hypoxic region, and it revealed that the hypoxic region had disappeared in four patients (4/5, 80%). Hypoxic tumors were clarified in 58% of our patients with stage I NSCLC. Re-oxygenation was observed at 1 month after SBRT with a probability of 80%.
|
Report
(4 results)
Research Products
(4 results)
-
-
-
[Presentation] Respiration-gated 18F-fluoromisonidazole PET/CT for stage I non-small cell lung cancer treated by stereotactic body radiotherapy.2015
Author(s)
Inoue T, Okamoto S, Watanabe S, Yasuda K, Katoh N, Harada K, Onimaru R, Shiga T, Tamaki N, Kuge Y, Shirato H
Organizer
The 57th Annual Meeting, American Society for Therapeutic Radiology and Oncology
Place of Presentation
Henry B. Gonzalez Convention Center, San Antonio, USA
Year and Date
2015-10-20
Related Report
Int'l Joint Research
-